AU2010259213A1 - EGFR and PAR2 regulation of intestinal permeability - Google Patents

EGFR and PAR2 regulation of intestinal permeability Download PDF

Info

Publication number
AU2010259213A1
AU2010259213A1 AU2010259213A AU2010259213A AU2010259213A1 AU 2010259213 A1 AU2010259213 A1 AU 2010259213A1 AU 2010259213 A AU2010259213 A AU 2010259213A AU 2010259213 A AU2010259213 A AU 2010259213A AU 2010259213 A1 AU2010259213 A1 AU 2010259213A1
Authority
AU
Australia
Prior art keywords
haptoglobin
zonulin
disease
sample
autoimmune disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010259213A
Other languages
English (en)
Inventor
Alessio Fasano
Simeon Goldblum
Karen Lammers
Terez Shea-Donohue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland at Baltimore
Original Assignee
University of Maryland at Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland at Baltimore filed Critical University of Maryland at Baltimore
Publication of AU2010259213A1 publication Critical patent/AU2010259213A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2010259213A 2009-06-10 2010-06-10 EGFR and PAR2 regulation of intestinal permeability Abandoned AU2010259213A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18566209P 2009-06-10 2009-06-10
US61/185,662 2009-06-10
PCT/US2010/001670 WO2010144140A2 (en) 2009-06-10 2010-06-10 Egfr and par2 regulation of intestinal permeability

Publications (1)

Publication Number Publication Date
AU2010259213A1 true AU2010259213A1 (en) 2012-01-19

Family

ID=43309408

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010259213A Abandoned AU2010259213A1 (en) 2009-06-10 2010-06-10 EGFR and PAR2 regulation of intestinal permeability

Country Status (7)

Country Link
EP (1) EP2440246A4 (zh)
JP (1) JP2012529508A (zh)
KR (1) KR20120031496A (zh)
CN (2) CN104940927A (zh)
AU (1) AU2010259213A1 (zh)
CA (1) CA2765075A1 (zh)
WO (1) WO2010144140A2 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120107329A1 (en) * 2009-06-10 2012-05-03 University Of Maryland, Baltimore EGFR and PAR2 Regulation of Intestinal Permeability
WO2022019298A1 (ja) 2020-07-22 2022-01-27 富士フイルム和光純薬株式会社 炎症性腸疾患の診断を補助する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458925B1 (en) * 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
CA2422881A1 (en) * 2000-10-13 2002-04-18 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
US7611480B2 (en) * 2003-04-24 2009-11-03 Levy Mark M Gastrointestinal bioreactor
EP1753880A4 (en) * 2004-05-14 2010-07-14 Univ California METHODS OF TREATING CANCER USING ANTI-WNT2 MONOCLONAL ANTIBODIES AND SHORT INTERFERING RNA
TW200639404A (en) * 2005-05-13 2006-11-16 Univerisy Of Maryland Baltimore Method of assessing the effectiveness of a treatment regimen

Also Published As

Publication number Publication date
WO2010144140A8 (en) 2012-01-26
CA2765075A1 (en) 2010-12-16
WO2010144140A4 (en) 2011-07-14
CN104940927A (zh) 2015-09-30
JP2012529508A (ja) 2012-11-22
WO2010144140A2 (en) 2010-12-16
CN102481362A (zh) 2012-05-30
WO2010144140A3 (en) 2011-05-19
KR20120031496A (ko) 2012-04-03
EP2440246A4 (en) 2013-08-28
EP2440246A2 (en) 2012-04-18

Similar Documents

Publication Publication Date Title
Marchesan et al. Role of inflammasomes in the pathogenesis of periodontal disease and therapeutics
Chen et al. Hydrogen alleviates mitochondrial dysfunction and organ damage via autophagy‑mediated NLRP3 inflammasome inactivation in sepsis
US20140363818A1 (en) EGFR and PAR2 Regulation of Intestinal Permeability
US20220305038A1 (en) Fucosylation and immune modulation in cancer
Chen et al. Atezolizumab alleviates the immunosuppression induced by PD‑L1‑positive neutrophils and improves the survival of mice during sepsis
Dakhlallah et al. Constitutive AKT activity predisposes lung fibrosis by regulating macrophage, myofibroblast and fibrocyte recruitment and changes in autophagy
CN113209303B (zh) Wwp1通过溶酶体途径降解癌蛋白muc1抑制肿瘤及其应用
Rahman et al. Alpha1-acid glycoprotein is contained in bovine neutrophil granules and released after activation
AU2010259213A1 (en) EGFR and PAR2 regulation of intestinal permeability
EP3586840A1 (en) Novel therapy
Park et al. Granulocyte colony-stimulating factor reduces the endoplasmic reticulum stress in a rat model of diabetic cardiomyopathy
Xi et al. The 2-(2-benzofuranyl)-2-imidazoline provides neuroprotection against focal cerebral ischemia-reperfusion injury in diabetic rats: Influence of microglia and possible mechanisms of action
Wang et al. ADP‐ribose transferase PARP16 mediated‐unfolded protein response contributes to neuronal cell damage in cerebral ischemia/reperfusion
Wang et al. Pyruvate kinase M2 nuclear translocation regulate ferroptosis-associated acute lung injury in cytokine storm
Bailey Genetic and Pharmaceutical Targeting of HIF-1α Enhances PD-L1 Expression in Normal Tissue while Repressing It in Cancer: An Optimal Strategy for Combination Immunotherapy
US20210052617A1 (en) Methods and compositions for treating pre-eclampsia
Mo THE ROLE OF INTERFERON GAMMA AND CTLA4 IN MELANOCYTE AND MELANOMA BIOLOGY
WO2023164548A1 (en) Il-6 inhibitor as treatment for nephropathy
Zhang CXCL10 and Its Receptor CXCR3 Promote Non-alcoholic Steatohepatitis through Mediating Inflammatory Cytokines and Autophagy
Tseng Lysosomal destabilization in retinal pigment epithelial cells activates the NLRP3 inflammasome and induces IL-1β secretion
Hackert et al. Platelet inhibition reduces tissue damage in acute pancreatitis
Di Candia The expression and function of RAGE and HMGB1 in airway structural cells in asthma
Fischer et al. CLASS I PI3K ISOFORMS δ AND γ REGULATE KEY RESPONSES OF CERULEIN-INDUCED PANCREATITIS. PI3Kδ IS NECESSARY FOR TRYPSIN ACTIVATION
Lankisch et al. Asymptomatic Hyperamylasemia and/or Hyperlipasemia: Their Incidence, Causes and Clinical Impact
Ujiki et al. Pancreatic cancer cell cycle arrest and apoptosis are induced by a novel depsipeptide sansalvamide analogue

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application